His experience also encompasses investing, operational and management roles across health-tech companies

MedGenome has announced the appointment of Dr. Amit Kakar, MD, from Novo Holdings to its Board of Directors. This announcement comes on the heels of MedGenome’s USD 50 million funding round led by Novo Holdings in August 2022. They have also appointed Navjeewan Khosla, Principal, Novo Holdings, as a board observer.

Dr Kakar is a Senior Partner, Head of Novo Holdings Asia, and a healthcare professional with over 30 years of experience across key verticals, including medical technology, R&D, manufacturing, pharmacy retail, drug discovery, clinical research, biotech, hospitals and diagnostic centers, and primary and specialty care centres, among others. His experience also encompasses investing, operational and management roles across health-tech companies.

"MedGenome’s journey in the field of genomics has been very impressive. The company’s mission to transform the future of personalised healthcare by making genetic testing affordable and accessible across the different strata of society and creating awareness among the clinician community is in line with Novo’s investment strategy. I am looking forward to working closely with the team and my fellow board members on this next exciting phase of MedGenome’s expansion journey," said Dr. Amit Kakar, Senior Partner, Head of Novo Holdings Asia.

Navjeewan Khosla, Principal, Novo Holdings, said, "We are very excited to partner with the MedGenome team. We believe in their vision to leverage the power of genomics for better management of inherited disorders. Personalised healthcare can now be made accessible and affordable to all."

"In embarking on the next phase of our journey, we are delighted to have Dr Amit and Navjeewan on board. Their vast industry knowledge and experience will be of significant support to take MedGenome to new heights as well as to foray into new geographical markets. Together, we can scale up access and affordability to state-of-the-art genomic testing," said Mahesh Pratapneni, Co-founder and Group CEO of MedGenome.

Previously, Dr. Amit served as Head of M&A and Business Development at Everlife Asia in Singapore, was Head of Healthcare Investments at Avenue Capital Group and served in several senior leadership roles at GE Healthcare, stated the company's statement.

As a member of the board of directors, he joins Neeraj Bhargava of Zodius Capital, Tejeshwi Sharma of Sequoia Capital, Sam Santhosh, the founder, Felix Olale from LeapFrog, as well as Mahesh Pratapneni, the Co-founder and Chief Executive Officer of MedGenome.

In addition to expanding its product offerings, MedGenome intends to enhance the reach of its key diagnostic services, including reproductive and oncology, as well as expand its bioinformatics and SaaS capabilities, the company stated.